Kosan is in early human trials of epothilone-D, a potent variant of a promising new class of chemotherapy drugs derived from an African soil bacteria, Sorangium cellulosum.
Epothilone has the potential to be even more effective against taxane resistance because it has a different chemical structure that may let it bind better with microtubules.